Taspoglutide
- Generic Name
- Taspoglutide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C152H232N40O45
- CAS Number
- 275371-94-3
- Unique Ingredient Identifier
- 2PHK27IP3B
- Background
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 370
- Registration Number
- NCT01051011
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2118
- Registration Number
- NCT01018173
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 756
- Registration Number
- NCT00909597
A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 305
- Registration Number
- NCT00823992
A Study of Taspoglutide in Type 2 Diabetic Patients
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00811460
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00809705
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1072
- Registration Number
- NCT00755287
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 666
- Registration Number
- NCT00754988
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00744367
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 373
- Registration Number
- NCT00744926
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath